Hook / Thesis
Centene Corporation (CNC) has been marked down with its peers after a messy membership print and a cautious outlook, but the stock now offers a blunt, quantifiable asymmetric trade: the business is generating meaningful free cash flow and is trading at knockdown multiples, while policy and reimbursement moves could meaningfully re-rate the shares over the next several weeks to months.
We think the best way to play this is a mid-term long trade: enter around $37.30, limit downside with a stop near $33.00, and target $50.00 if margins stabilize and Medicare tailwinds persist. That setup captures near-term technical support and a valuation rerating if CMS payment trends and membership stability improve.
What Centene Does and Why the Market Should Care
Centene is a large managed-healthcare operator focused on government-sponsored programs: Medicaid, Medicare Advantage and related specialty services, plus a pharmacy and benefits services segment. The company reported $49.73 billion in revenue in the fourth quarter of 2025, demonstrating scale; it also remains a top player in Medicaid and Medicare markets where reimbursement policy changes quickly alter earnings power.
Two structural facts matter here. First, Centene has sizeable free cash flow generation - the most recent snapshot shows free cash flow of $4.321 billion and an enterprise value of roughly $17.86 billion - which gives the company room to invest, delever or return capital even while membership fluctuates. Second, Medicare Advantage payment trajectories and risk adjustment rules are direct profit drivers. A meaningful uptick in capitation rates or favorable risk-score trends across the industry flows straight to the bottom line for large insurers.
Supporting Data Points
- Market cap sits around $18.34 billion with an enterprise value near $17.86 billion.
- Valuation metrics are compressed: price-to-sales roughly 0.09 and EV/EBITDA about 7.04.
- Free cash flow is strong at roughly $4.321 billion and price-to-free-cash-flow is about 4.25.
- Balance-sheet features: debt-to-equity ~0.87 and current ratio ~2.72 give liquidity and manageable leverage.
- Operational pain points include a drop in Medicaid membership from 13.00 million to 12.52 million and a higher health benefits ratio of 94.3% reported with the Q4 release.
Valuation Framing
At $37.30 the stock trades at unusually low income multiples because trailing EPS is distorted (the dataset shows an EPS figure that is meaningfully negative), but cash-flow metrics tell a different story. With free cash flow of $4.321 billion versus an enterprise value of ~$17.86 billion, Centene is trading at roughly a 4.1x EV / FCF equivalent - an attractive multiple for a company with scale in government-sponsored care.
EV/EBITDA of 7.04 is modest and reasonable for a large insurer with cyclical membership trends. Historically, insurers trade at higher multiples when revenue visibility improves or when CMS rate guidance is favorable; the recent CMS updates (noted below) introduce that re-rating risk-on scenario. In plain terms: the market has priced in a pessimistic near-term earnings outlook. If Centene delivers margin improvement or Medicare rates prove stronger than feared, the valuation can re-rate substantially without fundamental earnings growth needing to be dramatic.
Catalysts
- CMS payment updates: The April CMS announcement that raised 2027 Medicare Advantage capitation rates materially above expectations provides an industry-wide revenue tailwind. Even a modest uptick in MA rates improves Centene's revenue mix and risk-adjusted margins.
- Membership stabilization: If Medicaid membership stops falling and begins to stabilize, the headline risk that pushed sell-side sentiment lower abates quickly.
- Margin improvement through benefit ratio normalization: Management reported a health benefits ratio near 94.3% in Q4 2025. A return toward historical benefit ratios (lower percent) would unlock earnings quickly.
- Portfolio / cost actions or asset monetizations: Given strong free cash flow and a reasonable balance sheet, any announced efficiency program or non-core asset sale would improve investor sentiment and free up cash to reduce leverage or invest in growth.
- Macro / market flows: New product launches like single-stock leveraged ETFs that include Centene can amplify buying pressure in the short term.
Trade Plan (Actionable)
Trade direction: Long
Entry price: $37.30
Stop loss: $33.00
Target price: $50.00
Horizon: Mid term (45 trading days) - this trade is designed as a swing: enough time for CMS-related headlines to percolate, for membership data to print, and for margin signals to show in follow-up results or quarterly commentary. If the thesis plays out faster, tightening the stop and taking partial profits is prudent; if the stock approaches $50 before the 45-day mark, consider exiting or re-evaluating based on fresh data.
Why these levels? Entry near $37.30 captures the current trading level with a stop below near-term support around $33 to limit downside if membership erosion or margin deterioration accelerates. The $50 target assumes a re-rating toward more normalized insurer multiples (a move toward a mid-teen EV/EBITDA or improvement in forward FCF expectations) combined with stabilization in Medicaid membership and some Medicare payment tailwind realization.
Risks and Counterarguments
There are clear reasons the market has been skeptical and you should weigh them before buying:
- Membership decline can continue: Medicaid enrollment has fallen from 13.00 million to 12.52 million. Continued enrollment pressure would reduce revenue and leave the stock vulnerable to further multiple compression.
- High benefit ratio: The reported health benefits ratio of 94.3% compresses margins. If medical-cost trends remain elevated, earnings will be pressured despite any reimbursement improvements.
- Policy risk: Changes or delays in CMS payments or risk-adjustment methodologies could cut the expected Medicare tailwind and re-tighten market sentiment.
- Execution risk: Management must translate revenue and cash flow into sustained margin improvement; failure to control costs or poor mix shifts could negate valuation benefits.
- Sentiment and liquidity-driven moves: The presence of leveraged ETFs and elevated short-volume in certain sessions can produce volatile spikes that work against disciplined entries and stops.
Counterargument
Critics will say Centene's headline EPS and membership trends show a business that is structurally weaker and justify a discounted multiple. That’s partially valid: trailing GAAP metrics are noisy and can be punishing. But the counterpoint is straightforward - cash generation and a reasonable balance sheet provide a bridge while policy and membership trends normalize. If free cash flow stays near $4.3 billion and the company can demonstrate margin improvement over the next two quarters, the market will re-assess the multiple more quickly than earnings alone would suggest.
Signs That Would Change My Mind
I would reduce conviction or exit the trade if any of the following occur:
- Medicaid membership declines accelerate for another two consecutive quarters.
- Management revises 2026 adjusted EPS guidance materially below the previously signaled >$3.00 level.
- CMS issues guidance that materially reduces Medicare Advantage capitation rates relative to the recent positive announcement.
- Free cash flow falls sharply below the current multi-billion-dollar pace.
Conclusion
Centene offers a measurable swing-trade opportunity: strong free cash flow and a manageable balance sheet underpin a deep-value starting point, while recent CMS guidance and industry dynamics create a plausible path to re-rating. The trade is not without clear downside risk - membership and benefit ratios matter - but with a disciplined entry at $37.30, a stop at $33.00 and a mid-term target of $50.00, the risk-reward is asymmetric enough to justify a conviction-buy for disciplined investors looking for a 45-trading-day swing trade.
Key monitoring points: weekly CMS headlines, membership trends, quarterly health benefits ratio, and quarterly free cash flow prints. If these indicators trend positively, the case for a material upside re-rate strengthens.